Lv4
470 积分 2022-10-20 加入
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
12小时前
待确认
Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan
12小时前
待确认
Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor
14小时前
已完结
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
2个月前
已完结
Putative allosteric MEK1 and MEK2 inhibitors
8个月前
已完结
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
10个月前
已完结
Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials
10个月前
已完结
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics
11个月前
已完结
皖公网安备34019202002308
